ArticleNature medicine2025
Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers.
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Article
- Feasibility of remote self-administered cognitive assessment in an Alzheimer's disease treatment clinic.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Modernizing cognitive assessment in Alzheimer's disease.Nature aging · 2026Article
- Beyond memory capacity: A probabilistic, dual store model of visuospatial working memory.PLoS computational biology · 2026Article
- The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion-Tensor-Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review.Journal of magnetic resonance imaging : JMRI · 2026Review
- Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Combining p-tau217 and digital cognitive testing to predict cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Contextualizing Blood-Based Biomarkers for Dementia Globally.Journal of neurochemistry · 2026Review
- Estimated prevalence of underdiagnosed dementia in a multiethnic community-based study.The journal of prevention of Alzheimer's disease · 2026Article
- Plasma brain-derived p-tau217 for the identification of amyloid status in a memory clinic cohort.Journal of neurology · 2026Article
- Review
- Implementing plasma p-tau217 and cognitive testing for Alzheimer's screening in low-education populations in central China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Phosphorylated Tau Biomarkers in Alzheimer's Disease: From Early Detection to Clinical Potential-A Comprehensive Review.Molecular neurobiology · 2026Review
- Semi-Supervised Clustering for Identification of MCI and Dementia Cohorts with a Brief Digital Cognitive Assessment.Research square · 2026Article
- A pilot study of at-home online cognitive screening prior to primary care wellness visits for older adults.Frontiers in digital health · 2026Article
- Monoclonal antibodies for early Alzheimer disease: a long road to discovery and marketing approval, a short timeline for health systems to organise services.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Predictive Value of Digital Neuropsychological and Gait Assessments on Shunt Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus: Prospective Cohort Study.Journal of medical Internet research · 2025Article
- Clinical staging in Swedish primary care using the Amsterdam Instrumental Activities of Daily Living Questionnaire.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
After the clinical implementation of amyloid-β-targeting therapies for people with cognitive impairment due to Alzheimer's disease (AD), there is an urgent need to efficiently identify this patient population in primary care. Therefore, we created a brief and self-administered digital cognitive test battery (BioCog). Based on its sub-scores, a logistic regression model was developed in a secondary care cohort (n = 223) and then evaluated in an independent primary care cohort comprising 19 primary care centers (n = 403). In primary care, BioCog had an accuracy of 85% when using a single cutoff to define cognitive impairment, which was significantly better than the assessment of primary care physicians (accuracy 73%). The accuracy increased to 90% when using a two-cutoff approach. BioCog had significantly higher accuracy than standard paper-and-pencil tests (that is, Mini-Mental State Examination, Montreal Cognitive Assessment, Mini-Cog) and another digital cognitive test. Furthermore, BioCog combined with a blood test could detect clinical, biomarker-verified AD with an accuracy of 90% (one cutoff), significantly better than standard-of-care (accuracy 70%) or when using the blood test alone (accuracy 80%). In conclusion, this proof-of-concept study shows that a brief, self-administered digital cognitive test battery can detect cognitive impairment and, when combined with a blood test, accurately identify clinical AD in primary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.